HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.

Abstract
Notch signaling is implicated in prostate cancer progression and docetaxel resistance. Cui and colleagues describe the additive efficacy and mechanisms of a γ-secretase inhibitor, PF-03084014, and docetaxel in preclinical models of prostate cancer, suggesting the need for further clinical development of Notch pathway modulators in men with metastatic prostate cancer.
AuthorsTian Zhang, Andrew J Armstrong
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 21 Issue 20 Pg. 4505-7 (Oct 15 2015) ISSN: 1557-3265 [Electronic] United States
PMID26307134 (Publication Type: Journal Article, Comment)
Copyright©2015 American Association for Cancer Research.
Chemical References
  • Amyloid Precursor Protein Secretases
Topics
  • Amyloid Precursor Protein Secretases (antagonists & inhibitors)
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols (pharmacology)
  • Humans
  • Male
  • Prostatic Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: